Cambridge Investment Research Advisors
VVOS icon

Cambridge Investment Research Advisors’s Vivos Therapeutics VVOS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-768
Closed -$43K – 3324
2021
Q4 		$43K Buy
768
+288
+60% +$23.2K ﹤0.01% 3107
2021
Q3 		$48K Sell
480
-1,022
-68% -$107K ﹤0.01% 3026
2021
Q2 		$186K Buy
+1,502
New +$245K ﹤0.01% 2856

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Cambridge Investment Research Advisors's VVOS Position: Q1 2022 in Review

Cambridge Investment Research Advisors sold out of Vivos Therapeutics (VVOS) in Q1 2022, closing a stake of 768 shares — an estimated $43K sold.

Cambridge Investment Research Advisors first reported a position in VVOS in Q2 2021 and held it in 3 quarters. The position peaked at $186K in Q2 2021. 27 funds tracked by Wall St. Rank hold VVOS as of Q1 2022.

  • Cambridge Investment Research Advisors reported no remaining Vivos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 768 Vivos Therapeutics shares in Q1 2022, an estimated $43K.
  • Cambridge Investment Research Advisors first reported a position in Vivos Therapeutics in Q2 2021 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Vivos Therapeutics position peaked at $186K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2022, filed 12 May 2022.